Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:14 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 11,389 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of SIAN Nasal Spray in Healthy Adults

NCT05194358
View directory record Official record
Conditions
Cyanide Poisoning
Interventions
Stabilized Isoamyl Nitrite (SIAN)
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT00613626
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Placebo, ZD6474
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
19
States / cities
Newark, Delaware • Chicago, Illinois • Galesburg, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Nov 2, 2026, 9:14 AM EST
Active, not recruiting No phase listed Observational

Laser Prostatectomy Database and Registry

NCT00159406
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Registry and Database
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Nov 2, 2026, 9:14 AM EST
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

NCT03973333
View directory record Official record
Conditions
Select Advanced Solid Tumors
Interventions
IMC-C103C, Atezolizumab
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Completed No phase listed Observational

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

NCT05912933
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age

NCT05780047
View directory record Official record
Conditions
Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy, Bisphenol A, Phthalate Exposure, Survey
Interventions
Mail-in Urine Test for EDCs
Diagnostic Test
Lead sponsor
Million Marker Wellness, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
434 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1 Interventional

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

NCT05037149
View directory record Official record
Conditions
Solid Tumor
Interventions
STP707
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Niraparib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Burbank, California • Duarte, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1Phase 2 Interventional Results available

High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

NCT03508726
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Ascorbate
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab in T1DM

NCT05574335
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Siplizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Completed No phase listed Observational

Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

NCT01522833
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Nov 2, 2026, 9:14 AM EST
Recruiting No phase listed Observational

Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer

NCT07764133
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Not listed
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease

NCT00976352
View directory record Official record
Conditions
Pompe Disease
Interventions
rAAV1-CMV-GAA (study agent) Administration, RMST
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1 Interventional

Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

NCT03654547
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer
Interventions
TT-00420
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Nov 2, 2026, 9:14 AM EST
Active, not recruiting No phase listed Observational

Post Acute Sequelae of COVID-19

NCT04964115
View directory record Official record
Conditions
Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Interventions
Cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 4 Interventional Results available

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services

NCT01781806
View directory record Official record
Conditions
HIV Prevention
Interventions
emtricitabine 200mg/tenofovir 300mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1 Interventional

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

NCT03326752
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
DV281, Breath Actuated Nebulizer, DV281 (RP2D), Approved Anti-PD-1 Inhibitor
Drug · Device
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Nov 2, 2026, 9:14 AM EST
Completed No phase listed Observational

An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings

NCT05362149
View directory record Official record
Conditions
Non-metastatic Castration-resistant Prostate Cancer
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe

NCT06114238
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab AI, Itepekimab PFS
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Recruiting Phase 1 Interventional

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1
Drug
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

NCT00799604
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Nov 2, 2026, 9:14 AM EST
Completed No phase listed Observational

African Cancer Genome: GMD

NCT05754658
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Standard of Care
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

The Impact of 8 Weeks of a Digital Meditation Application on Work Stress

NCT03624348
View directory record Official record
Conditions
Stress, Psychological, Behavioral Symptoms
Interventions
meditation
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 2, 2026, 9:14 AM EST
Not listed Phase 2Phase 3 Interventional

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

NCT03662126
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Interventions
KRT-232, Best Available Therapy (BAT)
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Nov 2, 2026, 9:14 AM EST